| Bioactivity | LCS3 is a reversible and uncompetitive glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) inhibitor (IC50=3.3 µM and 3.8 µM, respectively). LCS3 shows anti-tumor activity, and induces apoptosis. LCS3 can be used in lung adenocarcinoma (LUAD) research[1]. |
| Invitro | LCS3 (5 nM-10 µM; 96 h) inhibits lung cancer cell lines, but not non-transformed lung cells[1].LCS3 (3 µM; 3, 6, and 12 h) induces ROS and NRF2 pathway activation in sensitive lung adenocarcinoma (LUAD) cells[1].LCS3 (3 µM; 96 h) selectively kills lung adenocarcinoma (LUAD) cell lines, in part through the induction of apoptosis[1]. Cell Viability Assay[1] Cell Line: |
| Name | LCS3 |
| CAS | 109844-92-0 |
| Formula | C11H7ClN2O4 |
| Molar Mass | 266.64 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |